Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Equity Average (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Equity Average for 6 consecutive years, with $300.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 33.51% to $300.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.2 million, a 33.51% increase, with the full-year FY2025 number at $276.7 million, up 16.94% from a year prior.
  • Equity Average was $300.2 million for Q4 2025 at GeneDx Holdings, up from $284.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $599.3 million in Q3 2022 to a low of -$544.2 million in Q2 2021.
  • A 5-year average of $212.3 million and a median of $271.2 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 783.01% in 2022, then tumbled 54.08% in 2023.
  • GeneDx Holdings' Equity Average stood at $389.6 million in 2021, then grew by 4.6% to $407.5 million in 2022, then plummeted by 40.83% to $241.1 million in 2023, then fell by 6.74% to $224.9 million in 2024, then skyrocketed by 33.51% to $300.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Equity Average are $300.2 million (Q4 2025), $284.7 million (Q3 2025), and $267.3 million (Q2 2025).